How big is the Asia-Pacific Oral Anti-Diabetic Drug Market?

The Asia-Pacific Oral Anti-Diabetic Drug Market size is expected to reach USD 25.37 billion in 2024 and grow at a CAGR of 3.10% to reach USD 29.56 billion by 2029. Read More

What is the current Asia-Pacific Oral Anti-Diabetic Drug Market size?

In 2024, the Asia-Pacific Oral Anti-Diabetic Drug Market size is expected to reach USD 25.37 billion. Read More

Who are the key players in Asia-Pacific Oral Anti-Diabetic Drug Market?

Sanofi, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc. and AstraZeneca are the major companies operating in the Asia-Pacific Oral Anti-Diabetic Drug Market. Read More

What years does this Asia-Pacific Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the Asia-Pacific Oral Anti-Diabetic Drug Market size was estimated at USD 24.58 billion. The report covers the Asia-Pacific Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Asia-Pacific Oral Anti-Diabetic Drug Market Share

Statistics for the 2023 & 2024 Asia-Pacific Oral Anti-Diabetic Drug market share, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Oral Anti-Diabetic Drug share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Asia-Pacific Oral Anti-Diabetic Drug Industry

The Asia-Pacific oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly and Company, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.